Wendy Davis
Family · Red Bluff, CANPI 1265005110
Payments from drug & device makers
Across 547 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$878
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$769
- Boehringer Ingelheim$664
- Daiichi Sankyo Inc.$624
- AstraZeneca$553
- plus $4K from 34 others
What the payments were for
- Food & beverage$11,317100%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,357 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 87 | $91,531 |
| JardianceEmpagliflozin | 94 | $61,238 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $44,688 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $36,682 |
| TrulicityDulaglutide | 33 | $36,468 |
| VraylarCariprazine Hcl | 21 | $31,846 |
| EliquisApixaban | 37 | $25,694 |
| OzempicSemaglutide | 24 | $20,988 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $18,553 |
| JanuviaSitagliptin Phosphate | 13 | $12,213 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $10,412 |
| MyrbetriqMirabegron | 18 | $10,304 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,485 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,699 |
| DexilantDexlansoprazole | 11 | $3,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $510 | $127,999120 claims |
| Boehringer IngelheimJardiance | $664 | $61,23894 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $477 | $43,16775 claims |
| AbbVieVraylar, Synthroid | $3,677 | $33,40040 claims |
| PfizerEliquis | $200 | $25,69437 claims |
| Novo NordiskOzempic | $878 | $20,98824 claims |
| AstraZenecaBreztri Aerosphere | $553 | $18,55329 claims |
| MerckJanuvia | $31 | $12,21313 claims |
| Astellas Pharma US IncMyrbetriq | $131 | $10,30418 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $17 | $3,40111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Red Bluff
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.